CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 24 enrolled
Drug / intervention
anidulafungin and voriconazoledrug
Likely dose
anidulafungin and voriconazole 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00940017
NCT00940017Phase 4Completed
CompareCT.gov

A Phase 4, Open Label Study To Assess The Bronchopulmonary Pharmacokinetics Of Anidulafungin And Voriconazole Following Intravenous Administration In Healthy Subjects

Pfizer·interventional·Posted Jul 15, 2009·Updated Feb 9, 2010

In Brief

A Phase 4 clinical trial evaluating anidulafungin and voriconazole for Aspergillosis and Candidemia. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The purpose of this study is to provide anidulafungin and voriconazole to healthy subjects to determine the drug concentration in the lung.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAspergillosis, Candidemia
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 15, 2009
Enrollment StartSep 1, 2008
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 17.0 years ago

Interventions

anidulafungin and voriconazoledrug

Subjects will be admitted to the clinical research unit on Day 0. Subjects will receive anidulafungin intravenously in a loading dose of 200 mg on Day 1, followed by maintenance doses of 100 mg Q24h on Day 2 and Day 3. Simultaneously, using a separate intravenous access, subjects will receive voriconazole in a loading dose of 6 mg/kg Q12h on Day 1, followed by a maintenance dose of 4 mg/kg Q12h on Day 2, and a 4 mg/kg morning dose on Day 3.